A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The purpose of this study is to evaluate the safety and preliminary efficacy of BMS-986403 in participants with relapsed and/or refractory chronic lymphocytic leukemia (R/R CLL) or small lymphocytic lymphoma (SLL).
Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma
DRUG: BMS-986403|DRUG: Fludarabine|DRUG: Cyclophosphamide
Number of participants with adverse events (AEs), Up to 2 years after BMS-986403 infusion|Number of participants with serious adverse events (SAEs), Up to 2 years after BMS-986403 infusion|Number of participants with clinical laboratory abnormalities, Up to 2 years after BMS-986403 infusion|Number of participants with dose-limiting toxicity (DLT), Up to 2 years after BMS-986403 infusion|Maximum-tolerated dose (MTD) based on the incidence of DLTs that occur during the DLT evaluation period, Up to 2 years after BMS-986403 infusion|Recommended Phase 2 Dose (RP2D) based on the incidence of DLTs that occur during the DLT evaluation period, Up to 2 years after BMS-986403 infusion
Overall response rate (ORR), Up to 2 years after BMS-986403 infusion|Complete remission rate (CRR), Up to 2 years after BMS-986403 infusion|Duration of response (DOR), Up to 2 years after BMS-986403 infusion|Duration of complete remission (DOCR), Up to 2 years after BMS-986403 infusion|Time to response (TTR), Up to 2 years after BMS-986403 infusion|Time to CR (TTCR), Up to 2 years after BMS-986403 infusion|Progression free survival (PFS), Up to 2 years after BMS-986403 infusion|Overall survival (OS), Up to 2 years after BMS-986403 infusion|Pharmacokinetics by polymerase chain reaction (PCR): Maximum concentration (Cmax), Up to 2 years after BMS-986403 infusion|Pharmacokinetics by PCR: Time to peak (maximum) concentration (Tmax), Up to 2 years after BMS-986403 infusion|Pharmacokinetics by PCR: Area under the curve (AUC), Up to 2 years after BMS-986403 infusion
The purpose of this study is to evaluate the safety and preliminary efficacy of BMS-986403 in participants with relapsed and/or refractory chronic lymphocytic leukemia (R/R CLL) or small lymphocytic lymphoma (SLL).